A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Drögemöller BI, Wright GEB, Trueman J et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Ondansetron is a highly effective antiemetic for the treatment of nausea and vomiting. However, this medication has also been associated with QT prolongation. Pharmacogenomic information on therapeutic response to ondansetron exists, but no investigation has been performed on genetic factors that influence the cardiac safety of this medication.
62 Admixed, Admixed American, African, East Asian, European, First Nations, Middle Eastern, South Asian, South East Asian or unknown ancestry cases, 195 Admixed, Admixed American, African, East Asian, European, First Nations, Middle Eastern, South Asian, South East Asian or unknown ancestry controls
Study Statistics
Key metrics and study information
AI-Generated Summary
AI-generated by DNAGENICSIndependent AI summary of health and genetic findings from the published study
Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.
AI Summary In Progress
Our AI-generated summary of this publication is being prepared. Please check back soon.